HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel

• Published in: Cell death & disease Vol. 13; no. 5; p. 429
• Main Authors: Sgubin, Michela, Pegoraro, Silvia, Pellarin, Ilenia, Ros, Gloria, Sgarra, Riccardo, Piazza, Silvano, Baldassarre, Gustavo, Belletti, Barbara, Manfioletti, Guidalberto
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 03-05-2022; Springer Nature B.V; Nature Publishing Group
• Subjects: 13; 38; 631/67/1347; 692/699/67/1347; Antibodies; Biochemistry; Biomedical and Life Sciences; Breast cancer; Cell Biology; Cell Culture; Cell migration; Chromatin; Cyclin-dependent kinase; Cyclin-dependent kinase inhibitor p27; Cyclin-dependent kinases; Enzyme inhibitors; Gene expression; HMGA1a Protein - genetics; HMGA1a Protein - metabolism; Humans; Immunology; Kinases; Life Sciences; Metastases; Metastasis; Microtubules; Microtubules - metabolism; Motility; Neoplasm Recurrence, Local - metabolism; Paclitaxel; Paclitaxel - pharmacology; Paclitaxel - therapeutic use; Proteins; Stathmin; Stathmin - genetics; Stathmin - metabolism; Statistical analysis; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - metabolism; Tumors; Xenografts
• ISSN: 2041-4889; 2041-4889
• DOI: 10.1038/s41419-022-04843-4

High Mobility Group A1 (HMGA1) is an architectural chromatin factor involved in the regulation of gene expression and a master regulator in Triple Negative Breast Cancer (TNBC). In TNBC, HMGA1 is overexpressed and coordinates a gene network that controls cellular processes involved in tumour development, progression, and metastasis formation. Here, we find that the expression of HMGA1 and of the microtubule-destabilizing protein stathmin correlates in breast cancer (BC) patients. We demonstrate that HMGA1 depletion leads to a downregulation of stathmin expression and activity on microtubules resulting in decreased TNBC cell motility. We show that this pathway is mediated by the cyclin-dependent kinase inhibitor p27
kip1
(p27). Indeed, the silencing of HMGA1 expression in TNBC cells results both in an increased p27 protein stability and p27-stathmin binding. When the expression of both HMGA1 and p27 is silenced, we observe a significant rescue in cell motility. These data, obtained in cellular models, were validated in BC patients. In fact, we find that patients with high levels of both HMGA1 and stathmin and low levels of p27 have a statistically significant lower survival probability in terms of relapse-free survival (RFS) and distant metastasis-free survival (DMFS) with respect to the patient group with low HMGA1, low stathmin, and high p27 expression levels. Finally, we show in an in vivo xenograft model that depletion of HMGA1 chemo-sensitizes tumour cells to paclitaxel, a drug that is commonly used in TNBC treatments. This study unveils a new interaction among HMGA1, p27, and stathmin that is critical in BC cell migration. Moreover, our data suggest that taxol-based treatments may be more effective in reducing the tumour burden when tumour cells express low levels of HMGA1.